Proven Brain Aneurysm Device Begins Pivotal U.S. Clinical Trial

IRVINE, CA – March 20, 2026 – A medical technology with a significant track record in Europe has officially entered the U.S. clinical arena, potentially heralding a new chapter for the treatment of brain aneurysms. WallabyPhenox announced this week that the first patient in the United States has been successfully treated as part of the PIANO IDE trial, a pivotal study evaluating its p48 and p64 MW HPC Flow Modulation Devices.

The landmark procedure was performed by Dr. Adel Malek, Chief of Neurovascular Surgery at Tufts Medical Center in Boston, a leading institution in neurological care. This event marks a critical step for a device family that is already the market leader in Germany and has been used to treat over 20,000 patients worldwide. For American patients and physicians, it signals the potential arrival of a new, highly anticipated option in the fight against a life-threatening condition.

“Initiating the PIANO IDE trial is an important milestone in our company’s history and demonstrates our commitment to bringing life-saving innovations to patients in the United States,” said Ruilin Zhao, CEO of WallabyPhenox, in a statement.

The Silent Threat and Its Evolving Treatment

Intracranial aneurysms, often described as weak, bulging spots on the wall of a brain artery, are a serious health concern. While many remain unruptured and asymptomatic, they are found in an estimated 3% of the adult population. A rupture can lead to a subarachnoid hemorrhage—a type of devastating stroke with high rates of mortality and long-term disability.

For decades, the standard of care for treating these aneurysms involved surgical clipping, an invasive procedure requiring a craniotomy to place a small metal clip at the aneurysm's base. While highly effective, it comes with the significant risks and recovery time of open brain surgery.

The last two decades have seen a paradigm shift toward less invasive endovascular techniques. Neurosurgeons can now thread catheters through arteries in the wrist or groin up into the brain. Initial methods involved packing the aneurysm sac with platinum coils to promote clotting. More recently, flow diversion has emerged as a revolutionary approach, particularly for large or complex aneurysms. Instead of treating the aneurysm sac itself, a fine mesh stent, or flow diverter, is placed in the parent blood vessel. This device redirects blood flow away from the aneurysm, causing it to gradually shrink and heal over time, effectively sealing it off from circulation.

Despite these advances, the U.S. market has had a limited number of approved flow diverter options, primarily dominated by devices from industry giants like Medtronic and Stryker. Physicians and patients alike have been eager for new technologies that could improve safety, efficacy, and ease of use.

A New Contender with Novel Features

The p48 and p64 MW HPC devices aim to be that new option. Building on the established principles of flow diversion, WallabyPhenox has incorporated several novel features designed to address some of the persistent challenges in endovascular treatment.

“The p48 and p64 MW HPC devices have been used in the treatment of more than 20,000 patients worldwide, with data from rigorous studies conducted outside the United States demonstrating consistently high aneurysm occlusion rates and low complication rates,” noted Gary Brogan, VP of Global Clinical & Regulatory Affairs.

Key innovations include:
* Movable Wire (MW) Technology: This unique feature is engineered to give surgeons greater control during deployment, allowing for more stable and precise positioning of the device—a critical factor for successful outcomes.
* Hydrophilic Polymer Coating (HPC): The device is coated with a polymer designed to reduce thrombogenicity, the tendency for blood clots to form on a foreign surface. This could potentially lower the risk of post-procedural stroke, a known complication of implantable neurovascular devices.
* Simplified Delivery: The devices are designed to be delivered through smaller microcatheters, simplifying procedural access and potentially allowing surgeons to treat aneurysms in more delicate or tortuous blood vessels.
* Enhanced Visibility: The implant's Nitinol wires are infused with a platinum core, making the entire device fully visible under X-ray (radiographic) guidance. This helps ensure accurate placement and full deployment.

“We are pleased to usher in this unique flow diverter that the U.S. physician community has been eagerly awaiting,” said Dr. Demetrius Lopes, a renowned neurosurgeon who serves as the National Principal Investigator for the PIANO trial.

The Rigorous Path to U.S. Approval

Bringing a new high-risk medical device to the U.S. market is a long and meticulous process. The PIANO trial is operating under an Investigational Device Exemption (IDE) from the Food and Drug Administration (FDA), which allows the devices to be used in a clinical study to gather essential data on their safety and effectiveness in American patients.

The involvement of top-tier medical centers and leading neurovascular specialists underscores the trial's significance. Dr. Malek, who performed the first procedure, is joined by a team of national principal investigators including Dr. Lopes, Dr. Jared Knopman, and Dr. Eytan Raz—all of whom are at the forefront of neurovascular medicine. Their participation lends substantial credibility to the trial and signals a high level of interest from the clinical community.

“We always welcome the opportunity to offer new innovations and technologies to our patients through cutting-edge clinical trials,” said Dr. Malek. “A device that proves to be safe, effective and efficient will only enhance our ability to treat intracranial aneurysms and ensure the best-possible outcomes for our patients.”

The data collected from the PIANO trial will be crucial for WallabyPhenox’s eventual submission for Premarket Approval (PMA) from the FDA, the most stringent regulatory pathway for medical devices. While the devices' extensive use in Europe provides a strong foundation of evidence, the FDA requires robust data from U.S. clinical trials to grant approval for widespread use.

Enrollment in the PIANO IDE trial is now ongoing at leading neurosurgical centers across the country. For now, the p48 and p64 MW HPC devices remain limited to investigational use in the United States, but their arrival marks a promising development for patients and a significant new dynamic in the U.S. neurovascular market.